Influence of adjuvant and antigen dose on protection induced by an inactivated whole vaccine against Neospora caninum infection in mice.
In this study, the protection afforded by a Neospora caninum inactivated vaccine formulated with three different adjuvants (water-in-oil emulsion, aluminum hydroxide with CpG oligodeoxynucleotides and aluminum hydroxide with ginseng extract) and three different parasite doses (10(5), 5 × 10(5) or 10(6) inactivated whole tachyzoites) was evaluated using a mouse model. Mice were immunized subcutaneously twice at three-week intervals with inactivated Nc-Spain 1H tachyzoites and challenged by intraperitoneal inoculation with 10(6) live Nc-1 tachyzoites. The efficacy of the immunization was evaluated in non-pregnant BALB/c mice on days 1 and 5 (acute infection phase) and days 14 and 30 (chronic infection phase) post-challenge. The results showed the ability of water-in-oil emulsion combined with inactivated 5 × 10(5) tachyzoites to induce protection against neosporosis during the chronic stage, limiting parasite multiplication in the brain. Aluminum hydroxide-ginseng extract and inactivated tachyzoites reduced the number of parasites circulating in the blood during acute phase but failed to limit the establishment of chronic infection. On the other hand, a dose-effect was observed in groups vaccinated with aluminum hydroxide-ginseng extract in which the lesion severity increased as the inactivated tachyzoite dose. This study demonstrates that efficacy can significantly vary depending on the adjuvant, the dose of antigen and the phase of N. caninum infection in which the vaccine is tested.
SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Avda Puerta de Hierro, Ciudad Universitaria s/n, 28040 Madrid, Spain.
Silvia
S
Rojo-Montejo
Esther
E
Collantes-Fernández
Javier
J
Regidor-Cerrillo
Antonio
A
Rodríguez-Bertos
Antoni
A
Prenafeta
Mercedes
M
Gomez-Bautista
Luis M
LM
Ortega-Mora
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000592:standards; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000008:administration & dosage* / Q000276:immunology; D001921:Brain / Q000469:parasitology / Q000473:pathology; D003048:Coccidiosis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D016054:DNA, Protozoan / Q000032:analysis / Q000302:isolation & purification; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007279:Injections, Subcutaneous / Q000662:veterinary; D008168:Lung / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D018688:Neospora / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D018512:Parasitemia / Q000469:parasitology / Q000662:veterinary; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000662:veterinary; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016054:DNA, Protozoan; D007074:Immunoglobulin G; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated